Pluristem muscle treatment meets endpoints in trial

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem's (PSTI +5%) PLX-PAD placenta-derived stem-cell therapy for muscle injuries appeared to be safe and effective in treating orthopedic injuries in a Phase I/II trial

"Patients treated with PLX-PAD had a greater improved change of maximal voluntary muscle contraction force than the placebo group," Pluristem says. The injured muscle studied was the gluteus medius in the buttock.

The trial participants who received the treatment showed a 300% improvement vs a placebo.